U.S. stock futures slightly higher after Christmas holiday
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
Go back to U.S. stock futures slightly higher after Christmas holiday
December 28, 2016 3:55 PM EST
BMO Capital analyst Do Kim reiterated an Outperform rating and rasied his price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $68.00 (from $61.00) as the firm's Spinraza estimates increase to reflect a faster ramp based on the broad approval and a higher price point... More
December 27, 2016 9:31 AM EST
Laidlaw analyst Yale Jen reiterated a Buy rating and raised its price target on Ionis Pharmaceuticals (NASDAQ: IONS) to of $65.00 (from $59.00) announced the FDA approved Spinraza as a spinal muscular atrophy (SMA) treatment in pediatric and adult (late-onset) patients. IONS earned a... More
December 27, 2016 9:26 AM EST
Needham & Company analyst Chad Messer reiterated a Buy rating and $64 price target on Ionis Pharmaceuticals (NASDAQ: IONS) and partner Biogen were granted FDA approval for SPINRAZA (nusinersen), a treatment for spinal muscular atrophy. SPINRAZA will have a broad label including both children and adults... More
